|
支气管哮喘的中西医诊疗进展
|
Abstract:
支气管哮喘(bronchial asthma, BA)是一种以气道慢性炎症为基本特征的异质性疾病,由多种细胞和细胞组分参与,包括结构细胞、功能细胞、细胞因子等。临床表现为反复发作的喘息、气急,伴或不伴胸闷、咳嗽等症状,同时可伴气道高反应性和可逆的气流受限。在我国,一项中国成人肺部健康研究报告提示我国20岁以上人群哮喘患病率为4.2%,哮喘患病率有逐年增长的趋势,但疾病的总体控制率偏低,而现代医学对于BA的发病原因及机制尚不完全清楚,目前大多采取对症治疗,常见的治疗药物主要为糖皮质激素、β2受体激动剂、茶碱、白三烯调节剂、抗胆碱能药、生物靶向药、过敏原特异性免疫疗法等。虽然有一定的治疗效果,但副作用显著。而中医药以辨证施治为原则,通过方药随证加减做到用药个体化,在改善症状、延缓疾病进展方面具有独特优势。现将查阅近年来相关文献,从对BA中西医研究的认识和治疗等方面的研究概况进行探讨并综述如下。
Bronchial asthma (BA) is a heterogeneous disease characterized by chronic airway inflammation, involving multiple cells and cellular components, including structural cells, functional cells, cyto-kines, and so on. The clinical manifestations include recurrent wheezing, shortness of breath, with or without chest tightness, cough, and other symptoms, as well as airway hyperresponsiveness and reversible airflow restriction. In China, a research report on adult lung health in China suggests that the prevalence of asthma in the population aged 20 and above is 4.2%. The prevalence of asthma is increasing year by year, but the overall control rate of the disease is relatively low. However, mod-ern medicine is not fully clear about the causes and mechanisms of BA, and currently, most people adopt targeted treatment. The common treatment drugs are mainly glucocorticoids β2 receptor agonists, theophylline, leukotriene modulators, anticholinergic drugs, biologically targeted drugs, allergen specific immunotherapy, etc. Although it has a certain therapeutic effect, the side effects are significant. Traditional Chinese medicine, based on the principle of syndrome differentiation and treatment, achieves personalized medication through the addition and subtraction of prescrip-tions according to the symptoms. It has unique advantages in improving symptoms and delaying disease progression. We will now review relevant literature in recent years to explore and summa-rize the research overview on the understanding and treatment of traditional Chinese and Western medicine in BA.
[1] | 李羽娟, 戴付敏, 马彩霞, 等. 中医结合肺康复对支气管哮喘肺功能的影响研究[J]. 实用中医内科杂志, 2023, 37(6): 117-119. |
[2] | 方莉, 李泽庚, 王传博, 等. 哮病内科证治考[J]. 实用中医内科杂志, 2021, 35(7): 109-112. |
[3] | 滑宬, 何明. 基于“风、痰、虚”理论辨证治疗支气管哮喘的新思路[J]. 中国社区医师, 2023, 39(4): 76-78. |
[4] | 龙华君, 帅文昊, 薛洪兴, 等. 柏正平分期论治哮病经验[J]. 湖南中医杂志, 2021, 37(7): 16-18. |
[5] | 周仲瑛. 中医内科学[M]. 第2版. 北京: 中国中医药出版社, 2007: 80-81. |
[6] | 张慧婷, 刘枫, 王一鸣, 刘伟. 支气管哮喘发作期患者中医证候与呼出气一氧化氮及肺功能因素相关性研究[J]. 中国中医急症, 2022, 31(9): 1346-1349. |
[7] | 殷凯, 宫晓燕, 王爽. 宫晓燕治疗哮病经验[J]. 吉林中医药, 2022, 42(10): 1163-1165. |
[8] | 常兴, 刘如秀. 基于“肺阳虚”探讨哮喘寒饮蕴肺证病机并从细胞自噬探讨其病理机制[J]. 上海中医药杂志, 2021, 55(2): 53-55. |
[9] | 王成娟, 张常喜, 马燕利, 张雄慧, 郭浩. 张常喜教授治疗支气管哮喘的经验举隅[J]. 光明中医, 2022, 37(12): 2131-2133. |
[10] | 陈延杰, 易亚乔. 从“肺系膜”论哮病伏痰犯膜的病机特点与分型分期论治规律[J]. 湖南中医药大学学报, 2022, 42(4): 624-628. |
[11] | 宫明学. 王檀教授治疗哮病(发作期)的临床经验总结[D]: [硕士学位论文]. 长春: 长春中医药大学, 2021. |
[12] | 董竞成, 李风森, 张炜, 等. 支气管哮喘中西医结合诊疗中国专家共识[J]. 中国中西医结合杂志, 2023, 43(1): 12-20. |
[13] | 陆德鹏. 王檀教授以潜镇法治疗哮病(风哮)的临床经验总结[D]: [硕士学位论文]. 长春: 长春中医药大学, 2021. |
[14] | 杨颖. 祛风宣痹方干预哮喘气道炎症的理论依据与效应机制研究[D]: [博士学位论文]. 南京: 南京中医药大学, 2022. |
[15] | 伍婷婷, 刘敏, 柏正平. 柏正平从风痰论治哮病发作期经验[J]. 湖南中医杂志, 2020, 36(3): 14-15. |
[16] | 闫雷雷. 益气化痰散寒方治疗哮病临床观察[D]: [硕士学位论文]. 南昌: 江西中医药大学, 2019. |
[17] | 候丹, 黄帅阳, 吕明圣, 等. 哮喘宁颗粒对支气管哮喘大鼠气道炎症反应的调节作用机制[J]. 上海中医药杂志, 2023, 57(3): 67-71. |
[18] | 梁松. 佐金平木法治疗支气管哮喘急性发作期(肝火犯肺证)的临床疗效观察及对FeNO水平的影响[D]: [硕士学位论文]. 哈尔滨: 黑龙江中医药大学, 2021. |
[19] | 彭艳君. 加味射干麻黄汤联合西药治疗支气管哮喘急性发作期(哮病发作期寒哮证)的临床疗效观察[D]: [硕士学位论文]. 福州: 福建中医药大学, 2020. |
[20] | 陈梦竹. 理中清心汤治疗支气管哮喘慢性持续期(脾肾阳虚, 心火独亢证)的临床观察[D]: [硕士学位论文]. 长春: 长春中医药大学, 2018. |
[21] | 史兆雯, 罗旭明, 王雄彪, 肖震炜. 芪仙汤联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘慢性持续期痰哮证疗效及对患者气道慢性炎症的影响[J]. 中华中医药学刊, 2023, 41(7): 80-83. |
[22] | 姚龙龙. 祛风止痉散对哮喘风痰哮患者临床疗效及气道炎症因子水平的影响[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2022. |
[23] | 杨红伟. 小青龙汤联合苏黄止咳胶囊治疗人支气管哮喘的疗效及对T淋巴细胞、炎症因子的影响[J]. 四川中医, 2023, 41(3): 58-61. |
[24] | 陈强, 江炼, 龚芹会. 射干麻黄汤联合西药治疗支气管哮喘的临床观察[J]. 云南中医中药杂志, 2018, 39(9): 52-55. |
[25] | 杨佳, 范亚丽. 中医内外兼用治疗儿童支气管哮喘的效果及对肺功能指标的影响[J]. 中国医学创新, 2022, 19(23): 5-8. |
[26] | 赵舒梅, 刘兰英, 王和生, 张聪. 穴位贴敷防治哮喘复发的免疫应答机制研究进展[J]. 山东中医杂志, 2020, 39(5): 520-524. |
[27] | 张瑞超. 苏黄止咳方联合温针灸治疗风寒哮证临床观察[J]. 光明中医, 2021, 36(18): 3100-3102. |
[28] | 张君, 邵素菊, 任重, 王培育, 华金双, 秦小永, 王庆波, 邵素霞. “三穴五针法”治疗寒饮伏肺型哮病的多中心临床研究[J]. 中华中医药杂志, 2018, 33(2): 797-800. |
[29] | 黎笑红, 黄巍, 谭杰武. 补脾益肺推拿手法治疗小儿哮喘缓解期的临床效果[J]. 内蒙古中医药, 2022, 41(3): 111-113. |
[30] | 赵静, 吴秀清. 小儿推拿联合药物雾化治疗小儿支气管哮喘慢性持续期患儿的疗效[J]. 中国药物经济学, 2022, 17(3): 66-68+72. |
[31] | 刘昕, 宾博平, 周婧, 宋京京, 潘伟莲, 董晓知. 加减二陈汤联合化痰膏穴位贴敷治疗痰哮证疗效观察及对患儿肺功能、炎性因子、免疫指标的影响[J]. 湖北中医药大学学报, 2021, 23(6): 71-73. |
[32] | 马彩英. 三伏灸辨证分型联合西药治疗支气管哮喘的对比研究[J]. 中西医结合心血管病杂志, 2018, 6(35): 183-185. |
[33] | 王珊, 程亚伟, 陈磊, 王立春, 黄剑秋. 温肺健脾化痰汤配合热敏灸对支气管哮喘慢性持续期痰哮证患者中医证候积分及Th17/Treg平衡的影响[J]. 陕西中医, 2022, 43(1): 58-61. |
[34] | 陈奕帆, 王雨欣, 顾雨菲, 等. 支气管哮喘气道炎症损伤中免疫失衡的研究进展[J]. 中国医科大学学报, 2023, 52(4): 371-374. |
[35] | Luo, W., Hu, J., Xu, W. and Dong, J. (2022) Distinct Spatial and Temporal Roles for Th1, Th2, and Th17 Cells in Asthma. Frontiers in Im-munology, 13, Article ID: 974066. https://doi.org/10.3389/fimmu.2022.974066 |
[36] | 秦子雯, 王珺, 彭召云, 等. 穴位疗法治疗支气管哮喘急性发作期的神经分子机制[J]. 实用心脑肺血管病杂志, 2023, 31(1): 102-106. |
[37] | Yin, L.M., Duan, T.T., Ulloa, L. and Yang, Y.Q. (2018) Ezrin Orchestrates Signal Transduction in Air-way Cells. Reviews of Physiology, Biochemistry and Pharmacology, 174, 1-23. https://doi.org/10.1007/112_2017_4 |
[38] | Liu, P.Y., Li, S. and Tang, L.L. (2021) Nerve Growth Factor: A Potential Therapeutic Target for Lung Diseases. International Journal of Molecular Sciences, 22, 9112. https://doi.org/10.3390/ijms22179112 |
[39] | 朱彬, 李丽琴. 布地奈德联合硫酸特布他林雾化吸入治疗支气管哮喘临床观察[J]. 基层医学论坛, 2016, 20(28): 3957-3958. |
[40] | 陈列, 凌媛. 布地奈德联合硫酸特布他林雾化吸入治疗支气管哮喘的临床综合评价[J]. 航空航天医学杂志, 2015, 26(10): 1196-1197. |
[41] | 杨丽华, 张国成. 呼吸道合胞病毒感染与支气管哮喘发病机制研究进展[J]. 中华实用儿科临床杂志, 2016, 31(21): 1675-1677. |
[42] | Panek, M., Pietras, T., Fabijan, A., Zio?o, J., Wieteska, ?., Ma?achowska, B., Fendler, W., Szemraj, J. and Kuna, P. (2015) The NR3C1 Glucocorticoid Receptor Gene Polymorphisms May Modulate the TGF-Beta mRNA Expression in Asthma Pa-tients. Inflammation, 38, 1479-1492. https://doi.org/10.1007/s10753-015-0123-3 |
[43] | Zu?ka-Prot, M. and Ma?lanka, T. (2017) Inhaled Glucocorticoid Treatment Prevents the Response of CD8+ T Cells in a Mouse Model of Allergic Asthma and Causes Their Depletion Outside the Respiratory System. International Immunopharmacology, 53, 63-72. https://doi.org/10.1016/j.intimp.2017.10.012 |
[44] | Ogawa, K., Tanaka, S., Limin, Y., Arata, N., Sago, H., Yamamoto-Hanada, K., Narita, M. and Ohya, Y. (2017) Beta-2 Receptor Agonist Exposure in the Uterus Associated with Subsequent Risk of Childhood Asthma. Pediatric Allergy and Immunology, 28, 746-753. https://doi.org/10.1111/pai.12805 |
[45] | Kelly, H.W. and Bisgaard, H. (2002) Leukotriene Modifiers. Pediatrics, 109, 170-171.
https://doi.org/10.1542/peds.109.1.170-a |
[46] | Rodrigo, G.J. (2018) Anticholinergics for Asthma: A Long History. Current Opinion in Allergy and Clinical Immunology, 18, 38-43. https://doi.org/10.1097/ACI.0000000000000408 |
[47] | 王雯, 施焕中. 噻托溴铵在支气管哮喘治疗中的地位[J]. 中华医学杂志, 2014, 94(16): 1207-1208. |
[48] | Tanaka, A. and Adachi, M. (2013) Bronchial Asthma: Progress in Di-agnosis and Treatments. Topics: I. Basic Knowledge; 1. Paradigm Shift in the Treatment of Asthma. Nihon Naika Gakkai Zasshi, 102, 1327-1332. |